Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price raised by equities researchers at JPMorgan Chase & Co. from $950.00 to $1,050.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 13.16% from the stock’s previous close.

Several other brokerages have also recently weighed in on REGN. Leerink Partners raised their price objective on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research note on Friday, July 31st. Zacks Research raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Raymond James Financial lifted their price target on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $872.00.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $927.89 on Friday. Regeneron Pharmaceuticals has a one year low of $591.52 and a one year high of $935.35. The stock’s fifty day moving average price is $793.30 and its two-hundred day moving average price is $738.05. The firm has a market cap of $95.54 billion, a price-to-earnings ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The firm had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $4.58 billion. During the same period in the prior year, the company earned $11.83 earnings per share. The company’s quarterly revenue was up 36.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the transaction, the executive vice president directly owned 12,003 shares in the company, valued at $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,093 shares of company stock valued at $6,506,845. Company insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in REGN. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. Armstrong Advisory Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 28 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $29,000. Trust Co. of Vermont purchased a new position in Regeneron Pharmaceuticals during the second quarter worth $29,000. Finally, Fiduciary Financial Advisors acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.